Cerenome (PSTV) Return on Capital Employed (2011 - 2026)
Plus Therapeutics (PSTV) posted quarterly Return on Capital Employed of 185.74% for Q1 2026, down 141521.0% year-over-year from N/an in Q1 2025, and up 37.07% quarter-over-quarter from 295.13% in Q4 2025.
Cerenome (PSTV) Return on Capital Employed (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Return on Capital Employed for 16 consecutive years, with 185.74% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 141521.0% year-over-year to 185.74%; the TTM figure through Mar 2026 stood at 185.74% (down 141521.0% YoY), while the FY2025 annual figure was 1832.1%, up 160742.0% from the prior year.
- Return on Capital Employed rose to 185.74% in Q1 2026 per PSTV's latest filing, from 295.13% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 1229.48% in Q1 2025 and bottomed at 1505.15% in Q3 2025.
- Historically, Return on Capital Employed has averaged 130.16% across 5 years, with a median of 169.44% in 2022.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 99748 bps — and 2025, when it tumbled 199083 bps.
- Plus Therapeutics' Return on Capital Employed stood at 169.44% in 2022, then tumbled by 390 bps to 829.45% in 2023, then jumped by 120 bps to 168.03% in 2024, then tumbled by 276 bps to 295.13% in 2025, then jumped by 37 bps to 185.74% in 2026.
- Business Quant data shows PSTV's Return on Capital Employed at 185.74% in Q1 2026, 295.13% in Q4 2025, and 1505.15% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | -314.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -185.74% |
| Dec 31, 2025 | -295.13% |
| Sep 30, 2025 | -1,505.15% |
| Jun 30, 2025 | -328.61% |
| Mar 31, 2025 | 1,229.48% |
| Dec 31, 2024 | 168.03% |
| Sep 30, 2024 | 485.68% |
| Jun 30, 2024 | 136.01% |
| Mar 31, 2024 | 628.03% |
| Dec 31, 2023 | -829.45% |
| Sep 30, 2023 | -469.92% |
| Jun 30, 2023 | -479.69% |
| Mar 31, 2023 | -294.80% |
| Dec 31, 2022 | -169.44% |
| Sep 30, 2022 | -122.42% |
| Jun 30, 2022 | -103.53% |
| Mar 31, 2022 | -76.06% |
| Dec 31, 2021 | -71.40% |
| Sep 30, 2021 | -89.81% |
| Jun 30, 2021 | -87.66% |